Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
REV1	rs3087386	AA + AG	cisplatin	efficacy	no	This SNP is not associated with event-free survival (p = 0.744) or overall survival (p = 0.189), as determined by recurrence or death. Mean follow-up time was 143 months.	Genotypes AA + AG are not associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype GG.	25748439	1447675738
REV1	rs3087399	CC + CT	cisplatin	efficacy	no	This SNP was not associated with event-free survival (p = 0.458) or overall survival (p = 0.707), as determined by recurrence or death, with a mean follow-up time of 143 months.	Genotypes CC + CT are not associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype TT.	25748439	1447675747
REV1	rs3087403	CT + TT	cisplatin	efficacy	yes	Presence of at least one T allele is associated with reduced event-free survival (p = 0.004) and overall survival (p < 0.001), with followup until recurrence or death, with a mean follow-up of 143 months.	Genotypes CT + TT are associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype CC.	25748439	1447675704